Sintilimab as adjuvant therapy for patients with resected HCC at high risk of recurrence

被引：0
|
作者：
Hindson, Jordan
机构：
[1] Nature Reviews Gastroenterology & Hepatology,
来源：
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY | 2024年 / 21卷 / 03期
关键词：
D O I：
10.1038/s41575-024-00904-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：141 / 141
页数：1
相关论文
共 50 条
  • [21] A phase 2, multicenter study to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in patients with HCC at high risk of recurrence after curative resection
    Liang, Tingbo
    Zhang, Zongli
    Zheng, Jinfang
    Wang, Yijun
    Zhang, Jialin
    Li, Bo
    Ma, Tao
    Xu, Yunfei
    Wu, Changxiong
    Sun, Quan
    Meng, Yiman
    Yang, Xiaoli
    CANCER RESEARCH, 2022, 82 (12)
  • [22] The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma
    Mooradian, Meghan J. J.
    Sullivan, Ryan J. J.
    CANCER, 2023, 129 (14) : 2117 - 2121
  • [23] A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma (HCC) who are at high risk of recurrence after curative hepatic resection
    Knox, J.
    Cheng, A.
    Cleary, S.
    Galle, P.
    Kokudo, N.
    Lencioni, R.
    Park, J.
    Zhou, J.
    Mann, H.
    Morgan, S.
    Liu, X.
    Chin, S.
    Vlahovic, G.
    Fan, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] Adjuvant therapy for resected high-risk colon cancer: Current standards and controversies
    Gill, Sharlene
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2014, 35 (03) : 197 - 202
  • [25] ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
    Sands, Jacob
    Mandrekar, Sumithra J.
    Oxnard, Geoffrey R.
    Kozono, David E.
    Hillman, Shauna L.
    Dahlberg, Suzanne Eleanor
    Sun, Zhuoxin
    Chaft, Jamie E.
    Govindan, Ramaswamy
    Gerber, David E.
    Gray, Jhanelle Elaine
    Malik, Shakun M.
    Mooney, Margaret M.
    Janne, Pasi A.
    Vokes, Everett E.
    Kelly, Karen
    Ramalingam, Suresh S.
    Stinchcombe, Tom
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Assessment of adjuvant therapy in resected head and neck cancer with high-risk features
    Ajmani, Gaurav S.
    Nocon, Cheryl C.
    Wang, Chi-Hsiung
    Bhayani, Mihir K.
    ORAL ONCOLOGY, 2017, 74 : 15 - 20
  • [27] Adjuvant therapy with donafenib plus anti-PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study)
    Chen, Yiwen
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Que, Risheng
    Yu, Jun
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Adjuvant TACE may not improve recurrence-free or overall survival in HCC patients with low risk of recurrence after hepatectomy
    Feng, Long-Hai
    Zhu, Yu-Yao
    Zhou, Jia-Min
    Wang, Miao
    Xu, Wei-Qi
    Zhang, Ti
    Mao, An-Rong
    Cong, Wen-Ming
    Dong, Hui
    Wang, Lu
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [29] Update on adjuvant therapy in completely resected NSCLC patients
    Lim, Jeong Uk
    Yeo, Chang Dong
    THORACIC CANCER, 2022, 13 (03) : 277 - 283
  • [30] Optimal Adjuvant Therapy for Patients with Resected Rectal Cancers
    Aubin, Francine
    Blanke, Charles D.
    CURRENT COLORECTAL CANCER REPORTS, 2010, 6 (04) : 180 - 182
12345